Drug intelligence / Profile preview

Tongfengkang

Development stage: Phase 2
Lead developer: Qingdao Haichuan Center for Innovative Biomedical Research
Modality: Small Molecules
Administration: Oral

Overview

Tongfengkang is a natural medicine candidate developed by the Qingdao Haichuan Innovative Natural Medicine Research Center for the treatment of primary acute gouty arthritis. Derived from traditional Chinese medicinal knowledge but developed as a modern pharmaceutical, it aims to address the intense inflammation and pain associated with acute gout flares. The drug's mechanism involves the suppression of inflammatory cytokines and the potential regulation of uric acid levels. It has undergone clinical evaluation in China, reaching Phase III trials, where it demonstrated efficacy in reducing joint swelling and pain scores in patients with acute gouty attacks.

Brand names: Tongfengkang
Other names: Tongfengkang Capsule痛风康

Targets

XO (Xanthine Oxidoreductase)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on Tongfengkang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tongfengkang.